This invention provides a treatment for osteomyelitis. Typical treatment involves surgical debridement to remove dead bone tissue, followed by long-term high dose treatment with intravenous vancomycin. This prolonged, high dose treatment often causes serious side effects. The inventor has created a method to target vancomycin directly to bone tissue. The antibiotic is encapsulated in a liposome. The liposome is surface modified by adding bone targeting moiety. The targeting moiety has a strong binding affinity for the main component of bone tissue (hydroxyapatite).
This invention will fit into the marketplace as a treatment. The end users of this treatment will be patients with osteomyelitis. This technology will be distributed across the market according to application and demand— developing countries have higher incidences of osteomyelitis, but the largest markets for treatments are in developed countries.
Features, Benefits, & Advantages:
• Targeted antibiotic delivery to bone tissue
• Decrease in side effects associated with traditional treatments
• Increased concentration of the antibiotic in bone tissue
• Lower necessary dose
• More effective treatment of osteomyelitis.